- Home
- GDEV vs ARCT Comparison
GDEV vs ARCT Comparison
Compare GDEV & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDEV
- ARCT
- Stock Information
- Founded
- GDEV 2009
- ARCT 2013
- Country
- GDEV Cyprus
- ARCT United States
- Employees
- GDEV N/A
- ARCT N/A
- Industry
- GDEV EDP Services
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- GDEV Technology
- ARCT Health Care
- Exchange
- GDEV Nasdaq
- ARCT Nasdaq
- Market Cap
- GDEV 268.7M
- ARCT 298.3M
- IPO Year
- GDEV N/A
- ARCT N/A
- Fundamental
- Price
- GDEV $15.41
- ARCT $12.53
- Analyst Decision
- GDEV Buy
- ARCT Strong Buy
- Analyst Count
- GDEV 2
- ARCT 8
- Target Price
- GDEV $70.00
- ARCT $52.33
- AVG Volume (30 Days)
- GDEV 27.1K
- ARCT 450.8K
- Earning Date
- GDEV 05-16-2025
- ARCT 05-12-2025
- Dividend Yield
- GDEV N/A
- ARCT N/A
- EPS Growth
- GDEV N/A
- ARCT N/A
- EPS
- GDEV 1.38
- ARCT N/A
- Revenue
- GDEV $420,933,000.00
- ARCT $143,680,000.00
- Revenue This Year
- GDEV N/A
- ARCT N/A
- Revenue Next Year
- GDEV $12.39
- ARCT $42.36
- P/E Ratio
- GDEV $11.17
- ARCT N/A
- Revenue Growth
- GDEV N/A
- ARCT 15.38
- 52 Week Low
- GDEV $8.60
- ARCT $8.04
- 52 Week High
- GDEV $42.76
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- GDEV 54.94
- ARCT 54.31
- Support Level
- GDEV $14.91
- ARCT $11.51
- Resistance Level
- GDEV $16.00
- ARCT $13.00
- Average True Range (ATR)
- GDEV 0.79
- ARCT 0.98
- MACD
- GDEV -0.11
- ARCT 0.08
- Stochastic Oscillator
- GDEV 42.71
- ARCT 57.74
About GDEV GDEV Inc.
GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.